WS
AVDL

Wedbush Securities’s Avadel Pharmaceuticals AVDL Stock Holding History

Wedbush Securities’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-35,535
Closed -$51K – 988
2019
Q1 		$51K Buy
+35,535
New +$80.4K 0.01% 892

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Wedbush Securities's AVDL Position: Q2 2019 in Review

Wedbush Securities sold out of Avadel Pharmaceuticals (AVDL) in Q2 2019, closing a stake of 35,535 shares — an estimated $51K sold.

Wedbush Securities first reported a position in AVDL in Q1 2019 and held it in 1 quarter. The position peaked at $51K in Q1 2019. 45 funds tracked by Wall St. Rank hold AVDL as of Q2 2019.

  • Wedbush Securities reported no remaining Avadel Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wedbush Securities sold 35,535 Avadel Pharmaceuticals shares in Q2 2019, an estimated $51K.
  • Wedbush Securities first reported a position in Avadel Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Wedbush Securities's Avadel Pharmaceuticals position peaked at $51K in Q1 2019.
  • 45 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2019.

Based on Wedbush Securities's 13F filing for Q2 2019, filed 1 Aug 2019.